KMT2A and acute myeloid leukemia: In the last years, many new molecular markers have been shown to affect AML prognosis (e.g., CEBP-alpha mutations, MLL rearrangements, WT-1 expression, BAALC gene overexpression, and IDH2 mutations) [5].